studies

la/mBC - HR-positive - 1st line (L1), HER inhibitor vs. all, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsSYSUCC-002, 2022 0.82 [0.65; 1.04] 0.82[0.65; 1.04]SYSUCC-002, 202210%392NAnot evaluable progression or deaths (PFS)detailed resultsSYSUCC-002, 2022 0.88 [0.71; 1.09] 0.88[0.71; 1.09]SYSUCC-002, 202210%392NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-11 12:29 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 352,354 - treatments: 712,429,903,472,969,902,1321,643,641,640,427,910,430,976,909,966,917,1013,1025,916,977,1029,1017,911,428,971,913,912,918,965,1067,978,915,914,973,974,702,1313,498,1314,368,1301,1412,1298,1299,1334,1332,1303,1325,1320,1305,1300,1429,1324,1335,1307,1322,1319,718,422,1304,421,1312,1326,1368,1373,1309,1302,1308